With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.

The FDA's OPDP has sternly cautioned AstraZeneca for misleading claims in the promotional materials of its Breztri Aerosphere inhalation aerosol. The U.S. Food and Drug Administration (FDA) has issued ...

An AstraZeneca sales tool overstates the efficacy of COPD treatment Breztri, the Food and Drug Administration’s promotional division charged in a warning letter. The 12-page detail aid is aimed at ...

Please provide your email address to receive an email when new articles are posted on . The FDA found that AstraZeneca made misleading claims about Breztri Aerosphere for COPD in sales material. These ...

Breztri can cost around $400 without insurance. Medicare drug plans may cover inhalers for COPD, including drugs like Breztri, but specific coverage and cost depend on the exact plan. Breztri ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The replicate, multicenter, randomized, double-blind, ...

Positive high-level results from the phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination ...

AstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage in triple-drug inhaler market. Can another round of ...

The cost of Breztri Aerosphere can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price. Save up to $28 per fill off of the ...

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies WILMINGTON, Del.--(BUSINESS WIRE)-- ...